Fabio A.B. Schutz

Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial

Robert J. Motzer, Ray McDermott, Se Hoon Park, Mauricio Burotto et autres

us, ie, kr, it, ps, es, jp, co, be, au, ca, pl, nl, br, at (code pays fourni par la source)

Efficacy of targeted therapies (TT) after HIF-2⍺ inhibitor-based treatment in advanced renal cell carcinoma (aRCC).

Patricia Rioja, Macarena Rey-Cárdenas, Jorge Esteban-Villarrubia, David Plata et autres

pe, fr, es, co, it, br (code pays fourni par la source)

IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer

R. Dent, Fabrice André, Anthony Gonçalvès, Miguel Martín et autres

sg, fr, es, gb, de, us, tr, Éthiopie, kr, pr, it, cn, ch, pt, ca (code pays fourni par la source)

180O IMpassion132 double-blind randomised phase III trial of chemotherapy (CT) ± atezolizumab (atezo) for early-relapsing unresectable locally advanced or metastatic triple-negative breast cancer (aTNBC)

R. Dent, Fabrice André, Anthony Gonçalvès, M. Martín Jiménez et autres

sg, fr, es, gb, de, us, tr, mx, kr, ch, pt, cn, ca (code pays fourni par la source)

Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update

Andrey Soares, Fernando Sabino Marques Monteiro, Karine Martins da Trindade, Adriano Gonçalves e Silva et autres

br, us (code pays fourni par la source)

Latin American Consensus for the Evaluation and Treatment of Patients With Metastatic/Locally Advanced Urothelial Carcinoma

Ray Manneh Kopp, Fernando Galanternik, Fabio A.B. Schutz, Fabio Kater et autres

co, ar, br, cr, pe, mx (code pays fourni par la source)

Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study

Enrique Grande, José Ángel Arranz, Maria De Santis, Aristotelis Bamias et autres

es, at, de, gr, jp, kr, it, ru, si, br, tw, us, cn, ca, gb, au (code pays fourni par la source)

Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study

Aristotelis Bamias, Ian D. Davis, Matthew D. Galsky, José Ángel Arranz et autres

gr, au, us, es, jp, kr, it, ru, si, br, tw, tr, ca, gb, at, de (code pays fourni par la source)

Supplementary Tables 1 through 4 from Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients

Guillermo de Velasco, Youjin Je, Dominick Bossé, Mark M. Awad et autres

Data from Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients

Guillermo de Velasco, Youjin Je, Dominick Bossé, Mark M. Awad et autres

Supplementary Tables 1 through 4 from Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients

Guillermo de Velasco, Youjin Je, Dominick Bossé, Mark M. Awad et autres

Data from Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients

Guillermo de Velasco, Youjin Je, Dominick Bossé, Mark M. Awad et autres